Quinton Fivelman
R & d Director @KURK
Signup · Get unlimited contacts
WORK HISTORY
R & d Director @KURK
Twickenham, GB
As R&D Director I am responsible for controlling, coordinating and carrying out research projects for Kurk. This includes new product, clinical and analytical research. I work closely with the team to ensure our innovative products are ahead of the competition, and they give customers the best results possible to unlock nature’s potential and optimise health.
EDUCATION
London School of Hygiene and Tropical Medicine, U. of London
Doctor of Philosophy - PhD, Medicine (Malaria genomics, drug resistance, drug development)
University of Cape Town
BSc(Med)(Hons), Pharmacology, Chemistry and Microbiology
SKILLS
ABOUT QUINTON FIVELMAN
Dr. Quinton Fivelman is a healthcare and life sciences innovator whose career has centred on building technologies and companies that deliver measurable, scalable positive impact. His work spans medtech, diagnostics, genomics, Femtech, cleantech and AI.For iusegenius, his track record represents the ideal blend of scientific rigour, commercial execution, and mission aligned innovation - the kind of founder operator profile that resonates strongly with positive impact founders and investors seeking scalable, evidence based solutions to global health, societal and sustainability challenges.Previously, as Chief Scientific Officer at London Medical Laboratory, he helped scale the pathology organisation from £400k to £30m revenue in two years, expanding access to blood tests and Covid diagnostics during a critical period for public health. He led governance and regulatory engagement with DHSC and CQC, authored over 200 reports, and provided expert commentary across Sky News and BBC.Through his consultancy Q5 Enterprises, Quinton has held leadership, consulting, and advisory roles across cutting edge medtech and digital health companies including Diagu (AI pathology), Allelica (genomic risk prediction), and Baby2Body (Femtech). His work spans the full innovation value chain - from R&D and IP commercialisation to due diligence, market assessments, and global market entry.Across his career, he has operated along the full innovation value chain - from early stage R&D and IP commercialisation to due diligence, fundraising, and global market entry. Quinton has co founded and exited ventures, including the diagnostic medtech company MediWiSe, acquired for over £2.5m by Meta Materials Inc, which later IPO’d on NASDAQ. His leadership in cleantech (ADFerTech) and AI enabled platforms (Visii) further demonstrates his ability to build commercially successful companies that also deliver measurable positive impact.His scientific foundation includes a PhD in Medicine from the London School of Hygiene & Tropical Medicine, where he contributed to pioneering malaria genomics research as part of the Wellcome Trust Malaria Functional Genomics Initiative.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.